Multiple Sclerosis (MS) Drug Market

Reuters  Apr 24  Comment 
Biogen Inc posted lower-then-expected quarterly profit and revenue as its key oral multiple sclerosis (MS) drug Tecfidera showed signs of slowing growth, sending the company's shares down 3 percent in premarket trading on Friday.
Benzinga  Apr 22  Comment 
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today presented data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). Safety data showed rHIgM22 was well-tolerated in each of...
MedPage Today  Apr 21  Comment 
(MedPage Today) -- Researcher creates new, visually appealing model of multiple sclerosis.
Benzinga  Apr 21  Comment 
Today Biogen (NASDAQ: BIIB) announced new data from the ATTAIN study which demonstrate the long-term safety and efficacy of PLEGRIDY® (peginterferon beta-1a) over three years in people with relapsing-remitting multiple sclerosis (RRMS). The...
New York Times  Apr 17  Comment 
About 10 drugs are now approved to treat multiple sclerosis, and their prices are rising sharply. The generic Copaxone could help keep prices of all the drugs in check.
Benzinga  Apr 17  Comment 
Receptos Inc (NASDAQ: RCPT) extended its gains Friday a day after it published positive safety results from a study of its colitis drug. The San Diego-based company is up about 56 percent in the past three months and changed hands recently at...
Reuters  Apr 17  Comment 
An experimental drug comprising of a high-dose formulation of the food additive biotin has successfully helped patients with progressive multiple sclerosis in a major...
New York Times  Apr 16  Comment 
Ten drugs are now approved to treat multiple sclerosis but none of them has had a generic equivalent. It is possible that the introduction of the generic Copaxone could help keep prices of all the drugs in check.
FierceBiotech  Apr 15  Comment 
Biogen's latest treatment for multiple sclerosis helped repair damaged nerve tissue in a Phase II study, an incremental victory for a novel therapy that has a long way to go.
Forbes  Apr 14  Comment 
Results from using Biogen’s experimental nerve repair drug in a disease of the eye were “mildly encouraging,” experts say, keeping alive the hope that the medicine might work in multiple sclerosis.


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki